Circulating tumour cell capture
Fishing whole cancer cells out of a blood sample to count them or study them; the count is prognostic in breast, prostate and colorectal cancer.
Overview
Circulating tumour cells (CTCs) are rare cells shed by tumours into blood, roughly one per billion blood cells. The CellSearch system, cleared by the FDA in 2004, enriches them by EpCAM antibody capture and counts them; higher counts predict shorter survival in metastatic breast, prostate and colorectal cancer. Microfluidic and size-based methods capture EpCAM-negative cells, and single CTC sequencing and culture are used in research; CTC counts have not yet changed treatment in randomised trials.
How it works
Immunomagnetic or microfluidic enrichment of cells by surface antigen, size or deformability, followed by staining and enumeration or molecular analysis.
- Whole cells allow protein, RNA and functional study
- Prognostic in several metastatic cancers
- Repeatable from blood
- Very rare cells, low yield
- Antibody capture misses cells that have lost EpCAM
- Changing therapy on CTC counts has not improved outcomes in trials
Latest papers
topQuery for this technology: (TITLE:"Circulating tumour cell capture" OR ABSTRACT:"Circulating tumour cell capture") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Circulating tumour cell capture, not a curated reading list.
Similar pages
not linked directly; found by shared links- CompanyUniversal DX
Shares Liquid biopsy (ctDNA), Colorectal cancer.
- CompanyX-Zell
Shares Liquid biopsy (ctDNA), Prostate cancer.
- IdeaA blood test for the pre-metastatic niche
Shares Liquid biopsy (ctDNA), Colorectal cancer, HR-positive / HER2-negative breast cancer.
- IdeaProstate active surveillance without scheduled biopsies: MRI and blood tests decide
Shares Liquid biopsy (ctDNA), Prostate cancer.
- CompanyHelio Genomics
Shares Liquid biopsy (ctDNA), Colorectal cancer.
- PersonSarah-Jane Dawson
Shares Liquid biopsy (ctDNA), HR-positive / HER2-negative breast cancer.
- TechnologyCell-free DNA methylation tests
Shares Liquid biopsy (ctDNA), Colorectal cancer.
- IdeaLook for the resistant sub-population before the first dose
Shares Liquid biopsy (ctDNA), Colorectal cancer, HR-positive / HER2-negative breast cancer.